CSChristian Stocker

Christian Stocker

*This is an algorithmically generated author record based on publicly available information.

Christian Stocker has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

    by Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Christian Stocker, Alexander Rau, Kirsten Richter, Andreas Katopodis, Christoph Huber

    Background Targeting of stimulatory cytokines to PD-1 expressing tumor infiltrating lymphocytes (TILs) is a promising approach to reinvigorate antitumor immune responses. Currently, PD-1 checkpoint inhibitors (CPIs) have been established as the standard of care for many cancer indications. Here we present ANV600, a bispecific IL-2Rβ/γ agonist that employs a unique non-blocking PD-1 targeting arm. This is a first example that demonstrates the therapeutic combination of existing PD-1 inhibitors with novel PD-1 directed stimulatory cytokines. Methods A fully human non-blocking anti-PD-1 antibody was identified and used to generate a PD-1 targeted IL-2Rβ/γ selective anti-IL-2 antibody/IL-2 fusion protein (ANV600). The ANV600 binding site on PD-1 was modelled using the Protean 3D software. Simultaneous binding of ANV600 and multiple existing PD-1 blocking antibodies was tested by surface plasmon resonance analysis and on PD-1 expressing cells by flow cytometry. For efficacy studies transgenic human PD-1 mice were implanted subcutaneously with B16F10 or MC38 mouse tumor cells and were treated with ANV600 monotherapy or combination with pembrolizumab or nivolumab. Tumor growth was monitored, and TILs analyses were performed by flow cytometry. Results Modelling of the binding site of ANV600 to PD-1 revealed that the epitope does not overlap with the PD-L1 binding domain and does not compete with a range of established PD-1 CPIs. This was confirmed in plate- and cell-based binding assays, where simultaneous binding of ANV600 and PD-1 CPIs to recombinant or cell surface PD-1 was demonstrated. Furthermore, ANV600 induced full STAT5 phosphorylation in a PD-1 expressing T cell line in the presence of saturating concentrations of pembrolizumab or nivolumab. In transgenic human PD-1 mice, ANV600 monotherapy led to marked tumor growth retardation in the B16F10 and MC38 subcutaneous tumor models, which are poorly responsive to PD-1 inhibitor therapy. In both models the pronounced antitumor effect was further increased when ANV600 was combined with pembrolizumab or nivolumab. Consistent with the antitumor efficacy, analysis of TILs revealed strong increases of PD-1+ pre-exhausted and cytotoxic CD8 T cells in tumors of ANV600 treated mice. Conclusions Separating PD-1 blockade from cytokine targeting allows precision dosage of the potent ANV600 cytokine therapeutic while maintaining sustained PD-1 blockade with established anti-PD-1 CPIs. Our data demonstrate proof of concept in mouse tumor models. ANV600 is currently in late preclinical development and the promising combination therapy data presented here warrants its clinical development as co-treatment with established PD-1 CPIs. Ethics Approval All animal experiments were approved by the Cantonal Veterinary Office Basel, Switzerland, and performed in accordance with the Swiss laws for animal welfare and protection and the ‘Ethical Principles and Guidelines for Experiments on Animals by the Swiss Academies of Arts and Sciences’.


  • Open Access

    Novel exported fusion enzymes with chorismate mutase and cyclohexadienyl dehydratase activity: Shikimate pathway enzymes teamed up in no man's land

    by Christian Stocker, Tamjidmaa Khatanbaatar, Luca Bressan, Kathrin Würth-Roderer, Gabriele Cordara, Ute Krengel, Peter Kast


  • Abstract 4127: ANV600 is a potent, Cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells

    by Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Kirsten Richter, Christian Stocker, Alexander Rau, Andreas Katopodis, Christoph Huber

    Non-alpha IL-2-based therapeutic modalities with preferential signaling through the IL-2 beta(CD122)/gamma(CD132) receptor are in clinical development and have the potential to substantially increase the therapeutic index of recombinant IL-2 (aldesleukin) for cancer therapy. ANV600 is a novel bispecific compound, which features an anti-IL-2 antibody/IL-2 fusion protein and a proprietary hPD-1 binding moiety for specific delivery of the non-alpha IL-2 to tumor antigen experienced PD-1+ T cells. Compared to the untargeted control, ANV600 has increased potency to induce STAT5 phosphorylation in human PD-1+CD8 T cells in vitro. At the same time, stimulation with ANV600 results in markedly reduced STAT5 phosphorylation on Treg cells compared to aldesleukin. In activated human PBMCs, ANV600 induces PD-1 co-internalization with the CD122-CD132 complex, reducing detectable PD-1 on CD8 and CD4 T-cells. Surface PD-1 levels decrease is not observed on cells incubated with untargeted bispecific compound. In transgenic human PD-1 mice ANV600 treatment leads to marked tumor growth retardation in the B16F10 and MC38 subcutaneous tumor models compared to untargeted compound and vehicle. Immunophenotyping of the tumor infiltrating lymphocytes revealed a dose-dependent increase of intratumoral stem-like PD-1+T cells and cytotoxic GrzB+PD-1+T cells in mice treated with ANV600. ANV600 has potent and selective effects on antigen-experienced CD8 T cells both in human PBMCs and mouse syngeneic tumor models. This agent may be a promising anti-tumor therapeutic against poorly immunogenic tumors and warrants further pharmaceutical development. Citation Format: Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Kirsten Richter, Christian Stocker, Alexander Rau, Andreas Katopodis, Christoph Huber. ANV600 is a potent, Cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4127.

  • Open Access

    Novel exported bifunctional fusion enzymes with chorismate mutase and cyclohexadienyl dehydratase activity: shikimate pathway enzymes teamed up in no man’s land

    by Christian Stocker, Tamjidmaa Khatanbaatar, Kathrin Würth-Roderer, Gabriele Cordara, Ute Krengel, Peter Kast

    Chorismate mutase (CM) and cyclohexadienyl dehydratase (CDT) catalyze two subsequent reactions in the intracellular biosynthesis of phenylalanine. Surprisingly, exported CMs and CDTs exist in bacterial pathogens. Here, we report the discovery of novel and extremely rare exported bifunctional fusion enzymes, consisting of fused CM and CDT domains. Such enzymes were found in only nine bacterial species belonging to non-pathogenic γ- or β-proteobacteria. In γ-proteobacterial fusion enzymes, the CM domain is N-terminal to the CDT domain, whereas in β-proteobacteria the order is inversed. The CM domains share 15-20% sequence identity with the AroQ γ class CM holotype of Mycobacterium tuberculosis (*MtCM), and the CDT domains 40-60% identity with the exported monofunctional enzyme of Pseudomonas aeruginosa (PheC). In vitro kinetics revealed a K m Aequoribacter fuscus , Janthinobacterium sp. HH01, and Duganella sacchari were crystallized and their structures refined to 1.6, 1.7, and 2.4 Å resolution, respectively. Neither the crystal structures nor size-exclusion chromatography show evidence for substrate channeling or higher oligomeric structure that could account for cooperation of CM and CDT active sites. The genetic neighborhood with genes encoding transporter and substrate binding proteins suggests that these exported bifunctional fusion enzymes may participate in signaling systems rather than in the biosynthesis of Phe.

  • Top Cited Papers

    An evolution-based model for designing chorismate mutase enzymes

    by William P. Russ, Matteo Figliuzzi, Christian Stocker, Pierre Barrat-Charlaix, Michael Socolich, Peter Kast, Donald Hilvert, Remi Monasson, Simona Cocco, Martin Weigt, et al.

    Learning from evolution: Protein sequences contain information specifying their three-dimensional structure and function, and statistical analysis of families of sequences has been used to predict these properties. Building from sequence data, Russ et al. used statistical models that take into account conservation at amino acid positions and correlations in the evolution of pairs of amino acids to predict new artificial sequences that will have the properties of the protein family. For the chorismate mutase family of metabolic enzymes, the authors demonstrate experimentally that the artificial sequences display natural-like catalytic function. Because the models access an enormous space of diverse sequences, such evolution-based statistical approaches may guide the search for functional proteins with altered chemical activities. Science , this issue p. 440